Oaktree Acquisition III Life Sciences sponsor plans conversion of 4,798,758 Class B shares to Class A
OACC•The sponsor plans to convert 4,798,758 Class B ordinary shares into Class A ordinary shares one-for-one before an extension takes effect. After conversion, it will hold 5,382,739 Class A shares and 1,000 Class B shares; shareholders will consider extending the business combination deadline on October 16, 2026.
1. Planned share conversion
Oaktree Acquisition III Life Sciences' sponsor plans to convert 4,798,758 Class B ordinary shares into Class A ordinary shares one-for-one before an extension takes effect. Shareholders will consider extending the business combination deadline on October 16, 2026.
2. Share and voting terms
After conversion, sponsor holdings will total 5,382,739 Class A ordinary shares and 1,000 Class B ordinary shares. The converted shares will retain Founder Share restrictions, including no redemption rights, and the sponsor's voting power will remain unchanged. Assuming 13,326,977 redemptions and the conversion, outstanding shares will total 11,254,791 Class A ordinary shares and 1,000 Class B ordinary shares.
